ArticleHistology and histopathology2026
Effect of ART1 on the efficacy of oxaliplatin in colorectal cancer under high-cholesterol conditions.
Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe growth of colorectal cancer (CRC) can be affected by cholesterol (CHO), which may inhibit the efficacy of oxaliplatin (OXA). A high-fat diet can upregulate phosphorylation by sphingosine kinase 1 (SPHK1)/sphingosine-1-phosphate (S1P)/sphingosine 1-phosphate receptor 1 (S1PR1) and promote tumour cell proliferation. Moreover, S1P activates signal transducer and activator of transcription 3 (STAT3), which plays a critical role in tumour cell proliferation. Knockdown of arginine-specific single ADP ribosyltransferase 1 (ART1) can delay the growth of CRC and promote the inhibitory effect of OXA on CRC cell proliferation. Consequently, in a high-CHO environment, this study aims to investigate the impact of ART1 knockdown in CRC cells treated with OXA and on the growth of transplanted tumours in mice
methodsImmunohistochemistry of CRC tissue revealed that, compared with that of normal blood lipids, ART1 expression in CRC tissue from patients with hypercholesterolaemia was higher. Based on CCK8 and EdU assays, we found that ART1 knockdown reduced the proliferation ability of CRC cells and decreased the volume of subcutaneously transplanted tumours in the high-CHO group. Finally, under high-CHO conditions, ART1 knockdown significantly reduced the protein expression levels of SPHK1, S1P, S1PR1, STAT3, and p-STAT3 in CT26 cells and transplanted tumours, as determined by western blotting.
resultsThese findings suggest that under high-CHO conditions, inhibition of ART1 expression can promote the inhibitory effect of OXA on CT26 cell proliferation, which may be related to the influence of ART1 on STAT3 expression through SPHK1/S1P/S1PR1.
conclusionsThis study is of great significance in improving the inhibitory effect of OXA on CRC cell proliferation in a high-CHO environment.
Indexed as
Identifiers
41346334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.